XAGE Longevity Health Holdings, Inc.
Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics · OTC · SEC CIK 1842939 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY60.3%
TTM net income YoY5.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin59.0%
Operating margin-343.6%
Net margin-404.8%
FCF margin—
EBITDA margin-340.0%
Returns
ROE—
ROA-286.0%
ROIC (approx.)—
Asset turnover0.71x
Leverage & solvency
Liabilities / assets924.4%
Debt / equity—
Current ratio0.07x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-183.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.91M | $50,318 |
| Cost of revenue | $818,051 | $6,357 |
| Gross profit | $1.09M | $43,961 |
| R&D expense | $788,888 | $1.05M |
| Operating income | -$7.11M | -$5.00M |
| Interest expense | $18,214 | $29,446 |
| Pretax income | -$6.87M | -$10.75M |
| Income tax | $36,262 | -$97,279 |
| Net income | -$6.91M | -$10.37M |
| EBITDA | -$7.03M | -$4.92M |
| EPS (basic) | -4.83 | -14.56 |
| EPS (diluted) | -4.83 | -14.56 |
| Weighted avg. shares (diluted) | 1.43M | 712,091 |
| Balance sheet | ||
| Cash & equivalents | $706,740 | $157,139 |
| Receivables | $36,500 | $4,096 |
| Inventory | $963,028 | $108,705 |
| Current assets | $1.95M | $955,554 |
| PP&E, net | $101,621 | $113,906 |
| Intangibles | $15,094 | $19,641 |
| Total assets | $2.37M | $1.47M |
| Current liabilities | $7.92M | $5.88M |
| Total liabilities | $8.23M | $6.19M |
| Shareholders' equity | -$5.87M | -$4.71M |
| Shares outstanding | 1.78M | 696,969 |
| Cash flow statement | ||
| Operating cash flow | -$3.33M | -$3.89M |
| Capital expenditure | $14,225 | — |
| Free cash flow | -$3.34M | — |
| Investing cash flow | -$164,225 | -$748,796 |
| Financing cash flow | $4.04M | $1.89M |
| Depreciation & amortization | $78,675 | $83,486 |
| Stock-based compensation | $692,790 | $827,043 |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.